Generation Lab has raised US$11m to expand its SystemAge platform for ageing diagnostics and clinic rollout, less than a year after launch.
The seed round, led by Accel, brings total funding to US$15m. Other backers include Samsung Next, Zone2, Aoki Labs, BYL Ventures and Markham Valley Ventures.
SystemAge estimates biological age — how well body systems function — from standard blood tests. It assesses 19 systems and uses DNA methylation patterns (chemical tags on DNA that influence gene activity).
Generation Lab reports adoption across more than 275 clinics, over 300m ageing-related data points collected, and a claimed diagnostic accuracy of 99.9 per cent. It also says many users are biologically older than their calendar age.
Alina Su, chief executive and co-founder, said: “We’re witnessing a fundamental shift from reactive to proactive healthcare — led by consumers. This funding allows us to accelerate our mission of making longevity diagnostics the standard of care globally. We’re not just measuring ageing; we’re creating the roadmap to reverse it.”
Kerry Wang, partner at Accel, said: “Alina, Michael and Irina are building with conviction and credibility in a space that demands both. Their SystemAge platform combines solid science with strong commercial progress, creating a new category in data-driven healthcare. This is only the beginning.”
Co-founder Dr Irina Conboy said: “While other platforms offer disease biomarkers, we’ve developed the first preventive health test detecting signals before symptoms appear. Our algorithms reveal which systems are ageing fastest and suggest precise interventions.”
The company cites early studies suggesting improvements after certain interventions, including reported reductions in “brain age” and reproductive system age following specific therapies, alongside benefits from anti-inflammatory diets, targeted fasting protocols and tailored exercise.